[Edaily Reporter KIM JI-WAN ] Psomagen, Inc.(950200)announced on the 24th that it had obtained a Clinical Laboratory Permit in the field of “Molecular Genetic Testing” from the New York State Department of Health on the 18th. This certification signifies that Psomagen, Inc. has met the most stringent regulatory standards in the United States and has received official recognition for its global-level quality and analytical accuracy.

With this certification, Psomagen, Inc. has secured the qualification to directly receive and analyze clinical samples within New York State.

In most parts of the U.S., a clinical laboratory can operate with only federal CLIA (Clinical Laboratory Improvement Amendments) certification. However, New York State is known to be virtually the only region that requires an additional state license.

Through this certification, Psomagen, Inc. has once again demonstrated the quality management system, scientific accuracy, and operational capabilities of its CLIA-certified laboratory. Based on this, the company expects to further strengthen its competitiveness in the U.S. clinical diagnostics market.

CEO Hong Soo stated, “This certification is a meaningful achievement that goes beyond simply enabling us to accept specimens in New York State; it is recognition that Psomagen, Inc.’s test quality and accuracy are among the best in the world.” He added, “Now that we can provide diagnostic services directly in New York State—one of the largest healthcare markets in the U.S.—we expect this to help expand our revenue and increase our market share.”

He added, “Using this as a springboard, we will continue to expand our clinical diagnostic service portfolio and focus our efforts on providing top-tier genomic analysis services.”